NAD+ Precursors (NMN/NR)

NAD+ (nicotinamide adenine dinucleotide) is a universal electron carrier and co-substrate for over 500 enzymatic reactions in human metabolism, but its role in the sirtuin and PARP enzyme families makes it a central regulator of aging biology. The sirtuins are a conserved family of seven NAD+-dependent deacylases that govern metabolic adaptation, DNA repair, mitochondrial biogenesis, circadian rhythms, and cellular stress responses. PARP1 and PARP2 are NAD+-consuming enzymes that detect and signal DNA strand breaks, initiating the strand break repair response. Both families require NAD+ as a consumed co-substrate, meaning their activity is directly limited by intracellular NAD+ availability. The age-related decline in NAD+ -- documented at approximately 50 percent between young adulthood and middle age in human blood and muscle -- therefore constitutes a systems-level suppression of these protective pathways, providing the molecular rationale for NAD+ precursor supplementation as an aging intervention.

Two NAD+ precursors dominate the current supplementation landscape: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are downstream intermediates in the NAD+ biosynthesis pathway. NR enters cells via nucleoside transporters and is phosphorylated to NMN by NR kinase (NMRK1/2), and NMN is subsequently adenylated to NAD+ by NMNAT enzymes. In human pharmacokinetic studies, oral NR at 300 to 1,000 mg per day consistently raises whole-blood NAD+ by 40 to 60 percent within 2 to 4 weeks. NMN shows similar efficacy in human trials at 250 to 900 mg per day. The two precursors have different transport pharmacology but ultimately converge on the same NAD+ pool, and direct comparative human trials have not established a clear superiority for either form at clinically relevant doses. A third precursor, nicotinamide (niacinamide), is less preferred because it generates a metabolite (methylnicotinamide) that can inhibit SIRT1 directly, partially blunting the intended benefit.

The dominant driver of NAD+ decline in aging tissues is not reduced biosynthesis but increased NAD+ consumption, primarily by two enzymes: PARP1 and CD38. PARP1 activity rises in aged cells as the burden of oxidative and replicative DNA damage accumulates, chronically consuming NAD+ as a byproduct of ADP-ribosylation at damage sites. CD38 is an NADase that increases dramatically with age and with chronic tissue inflammation, catalyzing the hydrolysis of NAD+ to nicotinamide and ADP-ribose as a byproduct of generating cyclic ADP-ribose (cADPR) for calcium signaling. Importantly, the primary intracellular NAD+ pool used by sirtuins and the pool consumed by PARP1 and CD38 are largely shared; this means that sustained PARP1 and CD38 activation directly starves sirtuins of their substrate. NAD+ precursor supplementation addresses the supply side of this equation, while CD38 inhibitors such as apigenin and quercetin address the consumption side, explaining the synergistic strategy of combining the two approaches.

The mitochondrial effects of NAD+ repletion are central to its proposed anti-aging benefits. SIRT3, the primary mitochondrial sirtuin, is activated by elevated NAD+ and deacetylates and activates key metabolic enzymes including the subunits of Complex I, Complex II, Complex III, and the TCA cycle. SIRT1, the cytoplasmic and nuclear sirtuin, deacetylates PGC-1alpha (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis, increasing mitochondrial DNA copy number, promoting the transcription of oxidative phosphorylation subunits encoded in both the nuclear and mitochondrial genomes, and improving the overall capacity for aerobic energy production. Human trials with NR in older adults have shown improvements in skeletal muscle mitochondrial function, reduced circulating inflammatory markers, and in some trials improved physical performance, providing clinical validation for the mechanistic rationale.

Mechanism of Action

NR enters cells via nucleoside transporters and is phosphorylated to NMN by NR kinases (NMRK1 and NMRK2), and NMN is subsequently adenylated to NAD+ by NMNAT enzymes present in the cytoplasm, nucleus, and mitochondria. In the human gut, NMN is largely converted to NR before intestinal absorption, with subsequent reconversion to NMN and then NAD+ intracellularly. Once NAD+ levels are elevated, the primary beneficiary enzymes are the sirtuins (SIRT1 through SIRT7), PARP1 and PARP2, and CD38. SIRT1 deacetylates PGC-1alpha to drive mitochondrial biogenesis, deacetylates FOXO3 to promote autophagy and stress resistance, deacetylates p53 to modulate the apoptotic threshold, and deacetylates WRN to support DNA repair. SIRT3 in the mitochondrial matrix deacetylates and activates the subunits of Complexes I, II, and III, IDH2, SOD2, and acetyl-CoA synthetase, improving oxidative phosphorylation efficiency and reducing mitochondrial oxidative stress.

The interplay between PARP1 and the sirtuins is central to understanding why NAD+ supplementation has age-relevance. As cells accumulate oxidative and replicative DNA damage with age, PARP1 activity rises chronically, consuming NAD+ as it ADP-ribosylates proteins at damage sites and recruits DNA repair machinery. This PARP1-driven NAD+ depletion directly starves SIRT1 and SIRT3 of their substrate, creating a vicious cycle in which impaired sirtuin activity leads to reduced DNA repair efficiency, increased DNA damage, more PARP1 activation, and further NAD+ depletion. CD38, an NADase whose expression increases with chronic inflammation and aging, accelerates this depletion by hydrolyzing NAD+ in the extracellular and intracellular space. NAD+ precursor supplementation addresses this cycle by replenishing the substrate pool, but the fullest intervention would combine precursor supplementation with CD38 inhibition to simultaneously increase NAD+ supply and reduce its degradation.

Clinical Evidence

Human clinical trials have consistently validated the pharmacological premise of NAD+ precursor supplementation: NR and NMN raise whole-blood and tissue NAD+ in middle-aged and older adults at well-tolerated doses, and this elevation correlates with measurable downstream biological effects. The 2016 Trammell et al. pharmacokinetic study in healthy adults confirmed that oral NR raises blood NAD+ in a dose-dependent manner. The 2018 Martens et al. crossover trial in 24 middle-aged and older adults showed that NR at 1,000 mg per day reduced systolic blood pressure and arterial stiffness in subjects with elevated baseline values. A 2020 trial by Dollerup et al. in overweight older men confirmed metabolic effects on skeletal muscle. Studies with NMN in older adults, including the 2021 Igarashi et al. trial and the 2023 Yi et al. trial, showed improvements in muscle insulin sensitivity, physical performance, and walking speed. The evidence base is consistent with the view that NAD+ repletion produces meaningful biological effects in aging humans, though the magnitude and clinical significance of these effects require further validation in larger and longer trials.